Clinical and epidemiological significance of carbapenem resistance in Acinetobacter baumannii infections

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 5, 2016, Pages 3127-3131

  Tal Jasper, Ruthy ^a   Katz, David E ^b   Amrami, Nadav ^c   Ravid, Dor ^c   Avivi, Dori ^c   Zaidenstein, Ronit ^a,c   Lazarovitch, Tsilia ^c   Dadon, Mor ^c   Kaye, Keith S ^d   Marchaim, Dror ^a,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

^c ASSAF HAROFEH MEDICAL CENTER   (Israel)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM; BETA LACTAMASE INHIBITOR; CARBAPENEM; CARBAPENEM DERIVATIVE; RNA 16S; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII; COHORT ANALYSIS; FUNCTIONAL STATUS; HOSPITAL MORTALITY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; VERY ELDERLY; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; GENETICS; KAPLAN MEIER METHOD; MICROBIAL SENSITIVITY TEST; MULTIVARIATE ANALYSIS; PATHOGENICITY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; HUMANS; KAPLAN-MEIER ESTIMATE; MICROBIAL SENSITIVITY TESTS; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RNA, RIBOSOMAL, 16S;

EID: 84964822223     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02656-15     Document Type: Article

References (34)

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. http://dx.doi.org/10.1086/595011.
2. Munoz-Price LS, Weinstein RA. 2008. Acinetobacter infection. N Engl J Med 358:1271-1281. http://dx.doi.org/10.1056/NEJMra070741.
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309-317. http://dx.doi.org/10.1086/421946.
4. Gilad J, Carmeli Y. 2008. Treatment options for multidrug-resistant Acinetobacter species. Drugs 68:165-189. http://dx.doi.org/10.2165/00003495-200868020-00003.
5. Reddy T, Chopra T, Marchaim D, Pogue JM, Alangaden G, Salimnia H, Boikov D, Navon-Venezia S, Akins R, Selman P, Dhar S, Kaye KS. 2010. Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system. Antimicrob Agents Chemother 54:2235-2238. http://dx.doi.org/10.1128/AAC.01665-09.
6. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18: 268-281. http://dx.doi.org/10.1111/j.1469-0691.2011.03570.x.
7. Marchaim D, Zaidenstein R, Lazarovitch T, Karpuch Y, Ziv T, Weinberger M. 2008. Epidemiology of bacteremia episodes in a single center: increase in Gram-negative isolates, antibiotics resistance, and patient age. Eur J Clin Microbiol Infect Dis 27:1045-1051. http://dx.doi.org/10.1007/s10096-008-0545-z.
8. Paul M, Weinberger M, Siegman-Igra Y, Lazarovitch T, Ostfeld I, Boldur I, Samra Z, Shula H, Carmeli Y, Rubinovitch B, Pitlik S. 2005. Acinetobacter baumannii: emergence and spread in Israeli hospitals 1997-2002. J Hosp Infect 60:256-260. http://dx.doi.org/10.1016/j.jhin.2005.01.007.
9. Fishbain J, Peleg AY. 2010. Treatment of Acinetobacter infections. Clin Infect Dis 51:79-84. http://dx.doi.org/10.1086/653120.
10. Peleg AY, Hooper DC. 2010. Hospital-acquired infections due to Gramnegative bacteria. NEngl J Med 362:1804-1813. http://dx.doi.org/10.1056/NEJMra0904124.
11. Munoz-Price LS, Zembower T, Penugonda S, Schreckenberger P, Lavin MA, Welbel S, Vais D, Baig M, Mohapatra S, Quinn JP, Weinstein RA. 2010. Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak. Infect Control Hosp Epidemiol 31:1057-1062. http://dx.doi.org/10.1086/656247.
12. Bonomo RA, Szabo D. 2006. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 43(Suppl 2):S49-S56.
13. Playford EG, Craig JC, Iredell JR. 2007. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect 65:204-211. http://dx.doi.org/10.1016/j.jhin.2006.11.010.
14. Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, Ryu SY, Heo ST, Jung DS, Rhee JY, Shin SY, Ko KS, Peck KR, Lee NY. 2007. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 59:525-530. http://dx.doi.org/10.1093/jac/dkl499.
15. Esterly JS, Griffith M, Qi C, Malczynski M, Postelnick MJ, Scheetz MH. 2011. Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. Antimicrob Agents Chemother 55:4844-4849. http://dx.doi.org/10.1128/AAC.01728-10.
16. Huang ST, Chiang MC, Kuo SC, Lee YT, Chiang TH, Yang SP, Ti Y, Chen TL, Fung CP. 2012. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 45:356-362. http://dx.doi.org/10.1016/j.jmii.2011.12.009.
17. Sheng WH, Liao CH, Lauderdale TL, Ko WC, Chen YS, Liu JW, Lau YJ, Wang LH, Liu KS, Tsai TY, Lin SY, Hsu MS, Hsu LY, Chang SC. 2010. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int J Infect Dis 14:e764-e769. http://dx.doi.org/10.1016/j.ijid.2010.02.2254.
18. Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M. 2009. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect Control Hosp Epidemiol 30:1186-1192. http://dx.doi.org/10.1086/648450.
19. Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ. 2007. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 26:793-800. http://dx.doi.org/10.1007/s10096-007-0371-8.
20. Martin ET, Tansek R, Collins V, Hayakawa K, Abreu-Lanfranco O, Chopra T, Lephart PR, Pogue JM, Kaye KS, Marchaim D. 2013. The carbapenem-resistant Enterobacteriaceae score: a bedside score to rule out infection with carbapenem-resistant Enterobacteriaceae among hospitalized patients. Am J Infect Control 41:180-182. http://dx.doi.org/10.1016/j.ajic.2012.02.036.
21. Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. 2005. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 11:22-29. http://dx.doi.org/10.3201/eid1101.040001.
22. Chopra T, Marchaim D, Johnson PC, Awali RA, Doshi H, Chalana I, Davis N, Zhao JJ, Pogue JM, Parmar S, Kaye KS. 2014. Risk factors and outcomes for patients with bloodstream infection due to Acinetobacter baumannii-calcoaceticus complex. Antimicrob Agents Chemother 58: 4630-4635. http://dx.doi.org/10.1128/AAC.02441-14.
23. Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. 2010. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 54:4851-4863. http://dx.doi.org/10.1128/AAC.00627-10.
24. Falagas ME, Kasiakou SK, Rafailidis PI, Zouglakis G, Morfou P. 2006. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother 57:1251-1254. http://dx.doi.org/10.1093/jac/dkl130.
25. Ku K, Pogue JM, Moshos J, Bheemreddy S, Wang Y, Bhargava A, Campbell M, Khandker N, Lephart PR, Chopra T, Hayakawa K, Martin ET, Abreu-Lanfranco O, Dhar S, Kaye KS, Marchaim D. 2012. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. Am J Infect Control 40:983-987. http://dx.doi.org/10.1016/j.ajic.2011.12.014.
26. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL. 2008. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36: 296-327. http://dx.doi.org/10.1097/01.CCM.0000298158.12101.41.
27. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383. http://dx.doi.org/10.1016/0021-9681(87)90171-8.
28. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA, Rice LB, Wagener MM, McCormack JG, Yu VL. 2004. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 140:26-32. http://dx.doi.org/10.7326/0003-4819-140-1-200401060-00008.
29. Bion JF, Edlin SA, Ramsay G, McCabe S, Ledingham IM. 1985. Validation of a prognostic score in critically ill patients undergoing transport. Br Med J (Clin Res Ed) 291:432-434. http://dx.doi.org/10.1136/bmj.291.6493.432.
30. Horan TC, Andrus M, Dudeck MA. 2008. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36:309-332. http://dx.doi.org/10.1016/j.ajic.2008.03.002.
31. Latibeaudiere R, Rosa R, Laowansiri P, Arheart K, Namias N, Munoz-Price LS. 2015. Surveillance cultures growing carbapenem-resistant Acinetobacter baumannii predict the development of clinical infections: a retrospective cohort study. Clin Infect Dis 60:415-422. http://dx.doi.org/10.1093/cid/ciu847.
32. Bogan C, Marchaim D. 2013. The role of antimicrobial stewardship in curbing carbapenem resistance. Future Microbiol 8:979-991. http://dx.doi.org/10.2217/fmb.13.73.
33. Carmeli Y, Lidji SK, Shabtai E, Navon-Venezia S, Schwaber MJ. 2011. The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study. Diagn Microbiol Infect Dis 70:367-372. http://dx.doi.org/10.1016/j.diagmicrobio.2011.03.009.
34. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. 1963. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 185:914-919. http://dx.doi.org/10.1001/jama.1963.03060120024016.